PATENT CLAIM ANALYSIS

Application Number: 16109130
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-08
Patent Classification: ["514", "04400A"]

Abstract:
The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.

Claim (Index 2):
The nucleic acid-lipid particle of  claim 1 , wherein the nucleic acid comprises a single-stranded or double-stranded DNA.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 96.0
- Lexical Diversity: 2.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14606905', '12828189', '15153487', '14642452', '13807288']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8662256515970078
- 35 USC 102 Novelty (BERT): 0.6036656737592395
- Combined Prediction Score: 0.839969653813231
- Mean Citation Score: 553.922962
- Max Citation Score: 653.8695
- Similarity Product: 447.4068907432258

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test